AtonRa Partners Decreases Stake in IQVIA Holdings Inc. (NYSE:IQV)

AtonRa Partners reduced its stake in IQVIA Holdings Inc. (NYSE:IQV) by 10.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,160 shares of the medical research company’s stock after selling 240 shares during the period. AtonRa Partners’ holdings in IQVIA were worth $500,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of IQV. Silver Oak Securities Incorporated grew its position in shares of IQVIA by 1,046.8% in the 4th quarter. Silver Oak Securities Incorporated now owns 2,844 shares of the medical research company’s stock worth $658,000 after buying an additional 2,596 shares during the last quarter. Stonebrook Private Inc. bought a new stake in shares of IQVIA in the 4th quarter worth approximately $706,000. Unique Wealth Strategies LLC bought a new stake in shares of IQVIA in the 4th quarter worth approximately $1,841,000. Consolidated Planning Corp grew its position in shares of IQVIA by 9.0% in the 4th quarter. Consolidated Planning Corp now owns 8,008 shares of the medical research company’s stock worth $1,853,000 after buying an additional 660 shares during the last quarter. Finally, Dohj LLC bought a new stake in shares of IQVIA in the 4th quarter worth approximately $943,000. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Stock Up 0.3 %

IQV stock traded up $0.60 during midday trading on Monday, hitting $235.48. The company’s stock had a trading volume of 740,092 shares, compared to its average volume of 967,241. The company has a market cap of $42.74 billion, a PE ratio of 32.22, a P/E/G ratio of 2.27 and a beta of 1.50. IQVIA Holdings Inc. has a 12 month low of $167.42 and a 12 month high of $261.73. The company has a current ratio of 0.86, a quick ratio of 0.86 and a debt-to-equity ratio of 2.12. The firm’s 50-day moving average is $245.28 and its 200-day moving average is $223.30.

IQVIA (NYSE:IQV) last posted its earnings results on Wednesday, February 14th. The medical research company reported $2.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.82 by $0.02. IQVIA had a net margin of 9.06% and a return on equity of 29.32%. The business had revenue of $3.87 billion for the quarter, compared to analysts’ expectations of $3.80 billion. During the same quarter in the prior year, the business earned $2.54 EPS. The business’s revenue for the quarter was up 3.5% compared to the same quarter last year. On average, equities research analysts forecast that IQVIA Holdings Inc. will post 10.12 earnings per share for the current fiscal year.

Insider Buying and Selling at IQVIA

In other IQVIA news, insider Eric Sherbet sold 1,000 shares of the stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $241.50, for a total value of $241,500.00. Following the transaction, the insider now owns 20,836 shares of the company’s stock, valued at $5,031,894. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other IQVIA news, insider Eric Sherbet sold 1,000 shares of the company’s stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $241.50, for a total transaction of $241,500.00. Following the completion of the sale, the insider now directly owns 20,836 shares of the company’s stock, valued at $5,031,894. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Ari Bousbib sold 31,678 shares of IQVIA stock in a transaction on Friday, March 1st. The stock was sold at an average price of $250.53, for a total transaction of $7,936,289.34. Following the transaction, the insider now owns 796,752 shares in the company, valued at approximately $199,610,278.56. The disclosure for this sale can be found here. In the last ninety days, insiders sold 41,285 shares of company stock worth $10,331,003. Insiders own 1.60% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on IQV shares. Truist Financial lifted their price objective on IQVIA from $286.00 to $297.00 and gave the stock a “buy” rating in a research report on Tuesday, February 27th. Guggenheim lowered IQVIA from a “buy” rating to a “neutral” rating in a research report on Thursday, February 15th. Robert W. Baird lifted their price target on IQVIA from $226.00 to $251.00 and gave the company a “neutral” rating in a research report on Thursday, February 15th. Barclays lifted their price target on IQVIA from $260.00 to $265.00 and gave the company an “overweight” rating in a research report on Thursday, February 15th. Finally, BTIG Research assumed coverage on IQVIA in a research report on Tuesday, February 13th. They set a “buy” rating and a $285.00 price target on the stock. Three equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $256.80.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.